Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition

Acute Myeloid Leukemia Clinical Trial

— LAM-BDD  

Official title:

Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition at Toulouse and Bordeaux University Hospital

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03284593
• Other study ID #: 14 7344 03
• Status: Active, not recruiting
• Start date: December 2014
• Est. completion date: December 2030

Study information

• Verified date: July 2020
• Source: University Hospital, Toulouse
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared patients treated with intensive chemotherapy or azacitidine within two centres.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 199
• Est. completion date: December 2030
• Est. primary completion date: December 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients with acute myeloid leukemia

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• intensive chemotherapy

• Azacitidine

Locations

Country	Name	City	State
France	University Hospital Bordeaux	Bordeaux
France	University Hospital Toulouse	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival	Survival times	2 years